SCHEDULE: ARK Investment Management Discloses 4.92% Stake in Veracyte

ARK Investment Management LLC and Catherine D. Wood have jointly disclosed a beneficial ownership of 4.92% in Veracyte, Inc.'s common stock.

Summary

• ARK Investment Management LLC and Catherine D. Wood jointly reported beneficial ownership of 3,887,547 shares of Veracyte, Inc. common stock.
• This beneficial ownership represents 4.92% of the class of securities.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change or update to a previous filing.
• The event requiring this filing occurred on December 31, 2025.
• ARK Investment Management LLC holds sole voting power over 3,728,954 shares and sole dispositive power over 3,887,547 shares.
• Catherine D. Wood holds shared voting power over 3,800,223 shares and shared dispositive power over 3,887,547 shares.
• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Veracyte, Inc.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership by a significant investment firm. While not directly impacting company operations, the disclosure of a substantial stake by ARK Investment Management and Catherine D. Wood could be interpreted as a positive signal by the market, indicating their continued conviction in Veracyte, Inc.

Future Outlook

NA

Industry Context

This filing indicates continued interest from a prominent growth-oriented asset manager, ARK Investment Management, in the biotechnology and diagnostics sector, specifically in Veracyte, Inc. This aligns with ARK's known investment strategy focusing on disruptive innovation within healthcare.

Stakeholder Impact

• Shareholders: May view the significant stake by ARK Investment Management as a positive signal, potentially influencing investor sentiment and stock price.
• Company Management: Awareness of a large, prominent institutional investor holding a significant stake.

Next Steps

• ARK Investment Management LLC and Catherine D. Wood will continue to monitor their investment in Veracyte, Inc.
• Further amendments to Schedule 13G would be filed if their beneficial ownership significantly changes (e.g., crosses a 1% threshold up or down, or if they decide to pursue an activist role requiring a Schedule 13D).

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership by ARK Investment Management LLC and Catherine D. Wood, indicating a significant stake in Veracyte, Inc. While the filing itself does not provide operational or financial performance data, the involvement of a prominent growth-oriented investor like ARK could be seen as a positive indicator of long-term potential. However, without further fundamental analysis of Veracyte's business, financials, and market position, a definitive 'buy' or 'sell' recommendation cannot be made solely based on this ownership disclosure. Therefore, a 'hold' recommendation is appropriate for existing investors, suggesting they maintain their position while monitoring future developments, and for potential investors to conduct further due diligence.

Keywords

Veracyte Inc., ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Common Stock, Investment Disclosure, Biotechnology, Diagnostics